Forte Biosciences, INC. (FBRX) — 8-K Filings

8-K Filings (19)

• 8-K Filing — Apr 9, 2026
• Forte Biosciences Files 8-K for Q1 2026 Results — Apr 1, 2026 Risk: low
  Forte Biosciences, Inc. filed an 8-K on April 1, 2026, reporting its financial results and condition for the period ending March 31, 2026. The filing includes f
• Forte Biosciences Files 8-K on Operations and Financials — Aug 14, 2025 Risk: low
  On August 14, 2025, Forte Biosciences, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing also included informatio
• Forte Biosciences Files 8-K for Material Agreement — Jun 25, 2025 Risk: medium
  On June 24, 2025, Forte Biosciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial sta
• 8-K Filing — Jun 23, 2025
• Forte Biosciences Files 8-K on Security Holder Vote Matters — May 30, 2025 Risk: low
  On May 29, 2025, Forte Biosciences, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as Toc
• Forte Biosciences Files 8-K on Financials — May 15, 2025 Risk: low
  Forte Biosciences, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial stateme
• Forte Biosciences Relocates Principal Executive Offices — Apr 18, 2025 Risk: low
  On April 18, 2025, Forte Biosciences, Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are now located at 3060 Pega
• Forte Biosciences Files 8-K on Financials — Apr 4, 2025 Risk: low
  Forte Biosciences, Inc. filed an 8-K on April 4, 2025, reporting on its results of operations and financial condition as of March 31, 2025. The filing includes
• Forte Biosciences Files 8-K: Director Changes & Officer Compensation — Jan 24, 2025 Risk: medium
  On January 24, 2025, Forte Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election o
• Forte Biosciences Files 8-K Report — Dec 3, 2024 Risk: low
  On December 3, 2024, Forte Biosciences, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Tocagen Inc., i
• Forte Biosciences Files 8-K: Material Agreement & Equity Sales — Nov 20, 2024 Risk: medium
  On November 19, 2024, Forte Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• Forte Biosciences Names New Director and CMO — Sep 20, 2024 Risk: medium
  Forte Biosciences, Inc. announced on September 17, 2024, the departure of Director Dr. David S. Scholl and the election of Dr. Jonathan S. Roth as a new directo
• Forte Biosciences Files 8-K on Security Holder Rights — Aug 30, 2024 Risk: medium
  On August 27, 2024, Forte Biosciences, Inc. filed an 8-K report detailing material modifications to the rights of security holders and other events. The filing
• Forte Biosciences Appoints New Officers, Director Departs — Aug 22, 2024 Risk: medium
  On August 20, 2024, Forte Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of director Dr. Jonathan S. Ro
• Forte Biosciences Files 8-K — Aug 14, 2024 Risk: low
  Forte Biosciences, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations, other events, and financial statements. The filing indicates th
• Forte Biosciences Files 8-K for Material Agreement — Jun 14, 2024 Risk: medium
  On June 11, 2024, Forte Biosciences, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company
• Forte Biosciences Files 8-K Report — May 13, 2024 Risk: low
  On May 13, 2024, Forte Biosciences, Inc. filed an 8-K report detailing significant corporate events. The filing includes information on the company's results of
• Forte Biosciences Files 8-K — Mar 18, 2024 Risk: low
  Forte Biosciences, Inc. filed an 8-K on March 18, 2024, reporting on results of operations, other events, and financial statements. The company, formerly known

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX